For those considering participating in a lymphoma clinical trial, it is important to understand what happens after the participant is no longer in the study. The study can end for some people before its planned duration is reached, or before the study’s endpoint is determined. Some participants may also want to continue with a treatment after the study is over. All of these issues are important to review with study coordinators before beginning a clinical trial. The Informed Consent Document also provides information about leaving a study or what to expect after the study is over.
